Indications and Management of Everolimus After Liver Transplantation

Transplantation Proceedings

Volumn 41, Issue 6, 2009, Pages 2172-2176

  Bilbao, I ^a   Sapisochin, G ^a   Dopazo, C ^a   Lazaro, J L ^a   Pou, L ^a   Castells, L ^a   Caralt, M ^a   Blanco, L ^a   Gantxegi, A ^a   Margarit, C ^a   Charco, R ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS; TACROLIMUS;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INDICATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER TOXICITY; LIVER TRANSPLANTATION; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; PRIORITY JOURNAL; SEPSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL ANALYSIS; SURVIVORS; TACROLIMUS; TIME FACTORS;

EID: 68949212927     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.087     Document Type: Article

References (7)

1. Neuhaus P., Klupp J., and Langrehr J.M. m-TOR inhibitors: an overview. Liver Transpl 7 (2001) 473
2. Chapman T.M., and Perry C.M. Everolimus. Drugs 64 (2004) 861
3. Gomez-Camarero J., Salcedo M., Rincon D., et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 6 (2007) 786
4. Levy G., Schmidli H., Punch J., et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12 and 36 month results. Liver Transpl 12 (2006) 1640
5. Bilbao I., Sapisochin G., Dopazo C., et al. Indications and management of m-TOR inhibitors after liver transplantation. In: Taylor C.B. (Ed). Immunosuppression: New Research (2009), Nova Science Publishers, New York 117
6. Fortin M.C., Raymond M.A., Madore F., et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporine-sirolimus combination. Am J Transplant 4 (2004) 946
7. Zimmerman M.A., Trotter J.F., Wachs M., et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 14 (2008) 633